Lumosa Therapeutics and CHI Memorial announce new study for acute stroke
TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke. This new drug combines clot-busting and nerve-prote...
2024-02-02 22:22
2843